References
- Zafonte R, Elovic EP, Lombard L. Acute care management of post-TBI spasticity. Journal of Head Trauma Rehabilitation 2004; 19: 89–100
- Bode RK, Heinemann AW. Course of functional improvement after stroke, spinal cord injury, and traumatic brain injury. Archives of Physical Medicine and Rehabilitation 2002; 83: 100–106
- Cook L, Smith DS, Truman G. Using Functional Independence Measure profiles as an index of outcome in the rehabilitation of brain-injured patients. Archives of Physical Medicine and Rehabilitation 1994; 75: 390–393
- Walker WC, Pickett TC. Motor impairment after severe traumatic brain injury: A longitudinal multicenter study. Journal of Rehabilitation Research and Development 2007; 44: 975–982
- Marshall S, Teasell R, Bayona N, Lippert C, Chundamala J, Villamere J, Mackie D, Cullen N, Bayley M. Motor impairment rehabilitation post acquired brain injury. Brain Injury 2007; 21: 133–160
- Kofler M, Quirbach E, Schauer R, Singer M, Saltuari L. Limitations of intrathecal baclofen for spastic hemiparesis following stroke. Neurorehabilitation Neural Repair 2009; 23: 26–31
- Meythaler JM, Clayton W, Davis LK, Guin-Renfroe S, Brunner RC. Orally delivered baclofen to control spastic hypertonia in acquired brain injury. Journal of Head Trauma Rehabilitation 2004; 19: 101–108
- Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle & Nerve 1997; 6(Suppl): S92–120
- Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. New England Journal of Medicine 1991; 324: 1186–1194
- Guettard E, Roze E, Abada G, Lemesle C, Vidailhet M, Laurent-Vannier A, Chevignard MP. Management of spasticity and dystonia in children with acquired brain injury with rehabilitation and botulinum toxin A. Developmental Neurorehabilitation 2009; 12: 128–138
- Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975; 1: 480–484
- Hagen C, Malkmus D, Durham P. Levels of cognitive functioning. In: Rehabilitation of the head injuried adult. Comprehensive physical management. Professional Staff Association of the Rancho Los Amigos Hospital, Inc, Downey, CA 1979)
- Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: A reliability study. International Disability Studies 1988; 10: 61–63
- Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540–542
- Barnes MP. Rehabilitation after traumatic brain injury. British Medical Bulletin 1999; 55: 927–943
- Singer BJ, Jegasothy GM, Singer KP, Allison GT, Dunne JW. Incidence of ankle contracture after moderate to severe acquired brain injury. Archives of Physical Medicine and Rehabilitation 2004; 85: 1465–1469
- Esquenazi A, Mayer N, Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. American Journal of Physical Medicine and Rehabilitation 2008; 87: 305–310
- Suputtitada A. Local botulinum toxin type A injections in the treatment of spastic toes. American Journal of Physical Medicine and Rehabilitation 2002; 81: 770–775
- Gordon MF, Barron R. Effectiveness of repeated treatment with botulinum toxin type A across different conditions. Southern Medical Journal 2006; 99: 853–861
- Ashford S, Turner-Stokes L. Goal attainment for spasticity management using botulinum toxin. Physiotherapy Research International 2006; 11: 24–34
- Lee HM, Chen JJ, Wu YN, Wang YL, Huang SC, Piotrkiewicz M. Time course analysis of the effects of botulinum toxin type a on elbow spasticity based on biomechanic and electromyographic parameters. Archives of Physical Medicine and Rehabilitation 2008; 89: 692–699
- Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache. 2003; 43(Suppl 1)S16–24
- Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L. BoTULS: A multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technology Assessment 2010; 14: 1–142, on behalf of the BoTULS investigators
- Blicher JU, Nielsen JF. Does long-term outcome after intensive inpatient rehabilitation of acquired brain injury depend on etiology?. NeuroRehabilitation 2008; 23: 175–183
- Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. Journal of Neurology 2002; 249: 76–84
- Abbruzzese G, Berardelli A. Neurophysiological effects of botulinum toxin type A. Neurotoxicity Research 2006; 9: 109–114